, Tracking Stock Market Picks
Enter Symbol:
Apricus Bioscience Inc (NEXM) [hlAlert]

down 94.56 %

Nexmed, Inc. (NEXM) rated Outperform with price target $3 by Oppenheimer

Posted on: Thursday,  Feb 14, 2008  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Apricus Biosciences Inc (NASDAQ: APRI) on 02/14/2008, when the stock price was $22.65. Since
then, Apricus Biosciences Inc has lost 94.57% as of 11/06/2015's recent price of $1.23.
If you would have followed this Oppenheimer's recommendation on APRI, you would have lost 94.56% of your investment in 2822 days.

NexMed, Inc. is a pharmaceutical and medical technology company. They develop and commercialize therapeutic products based on proprietary delivery systems. They are currently focusing their efforts on new and patented pharmaceutical products based on a penetration enhancement topical delivery technology known as NexACT(R), which may enable an active drug to be better absorbed through the skin.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy